{"id":742238,"date":"2012-03-15T08:00:00","date_gmt":"2012-03-15T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\/"},"modified":"2023-03-22T00:04:25","modified_gmt":"2023-03-22T04:04:25","slug":"merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\/","title":{"rendered":"Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr)"},"content":{"rendered":"<p class=\"bwalignc\">       Calibr Presents a New Paradigm for Academic-Industry        Cooperation     <\/p>\n<p>WHITEHOUSE STATION, N.J. &amp; SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Merck, known outside the United States and Canada as MSD, today        announced a collaboration to create the California Institute for        Biomedical Research (Calibr), an independent, not-for-profit        organization (501c3) established to accelerate the translation of basic        biomedical research into innovative, new medicines to treat disease.     <\/p>\n<p>       Calibr will be led by Peter G. Schultz, Ph.D., a world-renowned chemist        and biotechnology entrepreneur. The Institute will offer academic        scientists, around the world, a streamlined, efficient and flexible path        for translating their biomedical research into novel medicines.     <\/p>\n<p>       &#8220;Calibr represents a new paradigm for early-stage translational        research,&#8221; said Dr. Schultz, director of Calibr and Scripps Professor of        Chemistry at The Scripps Research Institute. &#8220;By leveraging the drug        discovery expertise and resources of Calibr, academic researchers will        have the opportunity to maximize the potential therapeutic value of        their research.&#8221;     <\/p>\n<p>       Calibr investigators will work collaboratively with academic scientists        to advance new discoveries to preclinical proof of concept at which        stage commercial partnerships will be sought for further development.     <\/p>\n<p>       Merck will provide funding to Calibr of up to $90 million over a period        of seven years. Merck has an option to obtain an exclusive commercial        license to any proteins or small molecule therapeutic candidates derived        from work conducted by Calibr.     <\/p>\n<p>       For any projects not licensed by Merck, Calibr will be free to seek        alternative sources of funding for further development. In addition, the        Institute plans to access funds from government and non-government        sources. Revenues derived from licenses will be shared between Calibr        and the collaborating institutions.     <\/p>\n<p>       Project proposals from the scientific community will be chosen on the        basis of novelty, biomedical impact and technical feasibility and        reviewed by a scientific advisory board headed by Christopher T. Walsh,        Ph.D., Hamilton Kuhn Professor, Department of Biological Chemistry and        Pharmacology, Harvard University. In addition, an independent board of        directors headed by John D. Diekman, Ph.D., founder and managing partner        of 5AM Ventures will oversee the activities of the Institute.     <\/p>\n<p>       &#8220;Effective translation of basic biomedical research is essential to        advancing the next generation of novel therapies,&#8221; said Peter S. Kim,        Ph.D., president, Merck Research Laboratories and member of Calibr        scientific advisory board. &#8220;Calibr will provide an important venue where        basic research and drug discovery scientists may leverage each others&#8217;        strengths in the fight against disease.&#8221;     <\/p>\n<p>       Calibr will be located in San Diego, Calif., in close proximity to The        Scripps Research Institute, Salk Institute, University of California,        San Diego and Sanford-Burnham Medical Research Institute. Calibr will be        equipped with the latest high through-put screening and imaging,        medicinal and protein chemistry and preclinical sciences capabilities.     <\/p>\n<p>       <b>About Calibr<\/b>     <\/p>\n<p>       The California Institute for Biomedical Research (Calibr), is an        independent, not-for-profit organization (501c3) established to        accelerate the translation of basic biomedical research into innovative,        new medicines to treat disease. It has been designed to provide        expertise and resources for academic scientists to maximize the        therapeutic potential of their discoveries. The institute was founded by        Peter G. Schultz, Ph.D., with funding from Merck. <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.calibr.org&amp;esheet=50204604&amp;lan=en-US&amp;anchor=www.calibr.org&amp;index=1&amp;md5=16c980baed12d04f3c41cfe136872a2b\" rel=\"noopener\">www.calibr.org<\/a>.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50204604&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=0916dbcf689c8de816f3c962701e2d1e\" rel=\"noopener\">vip2-msd.com\/merckcom-migrated<\/a>        and connect with us on Twitter, Facebook and YouTube.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that all of the expected synergies from the merger of Merck        and Schering-Plough will not be realized, or will not be realized within        the expected time period; the impact of pharmaceutical industry        regulation and health care legislation in the United States and        internationally; Merck\u2019s ability to accurately predict future market        conditions; dependence on the effectiveness of Merck\u2019s patents and other        protections for innovative products; and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50204604&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=0e4ff9aeab47249595c608a7c58bfe86\" rel=\"noopener\">www.sec.gov<\/a>).     <\/p>\n<\/p>\n<p><p>       Merck<br \/>Media:<br \/>Ian R. McConnell, 908-423-3046<br \/>or<br \/>Investors:<br \/>Carol        Ferguson, 908-423-4465     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck, known outside the United States and Canada as MSD, today announced a collaboration to create the California Institute for Biomedical Research (Calibr), an independent, not-for-profit organization (501c3) established to accelerate the translation of basic biomedical research into innovative, new medicines to treat disease. Calibr will be led by Peter G. Schultz, Ph.D., a world-renowned chemist and biotechnology entrepreneur. The Institute will offer academic scientists, around the world, a streamlined, efficient and flexible path for translating their biomedical research into novel medicines. &#8220;Calibr represents a new paradigm for early-stage translational research,&#8221; said Dr. Schultz, director of Calibr and Scripps Professor of Chemistry at The Scripps Research Institute. &#8220;By leveraging the drug discovery expertise and resources of Calibr, academic researchers will have the opportunity to maximize the potential therapeutic value of their research.&#8221; Calibr investigators will work<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[289,56],"class_list":["post-742238","news_item","type-news_item","status-publish","hentry","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr) - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr) - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck, known outside the United States and Canada as MSD, today announced a collaboration to create the California Institute for Biomedical Research (Calibr), an independent, not-for-profit organization (501c3) established to accelerate the translation of basic biomedical research into innovative, new medicines to treat disease. Calibr will be led by Peter G. Schultz, Ph.D., a world-renowned chemist and biotechnology entrepreneur. The Institute will offer academic scientists, around the world, a streamlined, efficient and flexible path for translating their biomedical research into novel medicines. &quot;Calibr represents a new paradigm for early-stage translational research,&quot; said Dr. Schultz, director of Calibr and Scripps Professor of Chemistry at The Scripps Research Institute. &quot;By leveraging the drug discovery expertise and resources of Calibr, academic researchers will have the opportunity to maximize the potential therapeutic value of their research.&quot; Calibr investigators will work\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\\\/\",\"name\":\"Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr) - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2012-03-15T08:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr) - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\/","og_locale":"en_US","og_type":"article","og_title":"Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr) - Merck.com","og_description":"Merck, known outside the United States and Canada as MSD, today announced a collaboration to create the California Institute for Biomedical Research (Calibr), an independent, not-for-profit organization (501c3) established to accelerate the translation of basic biomedical research into innovative, new medicines to treat disease. Calibr will be led by Peter G. Schultz, Ph.D., a world-renowned chemist and biotechnology entrepreneur. The Institute will offer academic scientists, around the world, a streamlined, efficient and flexible path for translating their biomedical research into novel medicines. \"Calibr represents a new paradigm for early-stage translational research,\" said Dr. Schultz, director of Calibr and Scripps Professor of Chemistry at The Scripps Research Institute. \"By leveraging the drug discovery expertise and resources of Calibr, academic researchers will have the opportunity to maximize the potential therapeutic value of their research.\" Calibr investigators will work","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:25+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\/","name":"Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr) - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2012-03-15T08:00:00+00:00","dateModified":"2023-03-22T04:04:25+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-partners-with-academic-scientists-and-biotechnology-entrepreneurs-to-create-the-california-institute-for-biomedical-research-calibr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr)"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"81eba7c5-0a5f-4b3b-89a0-d4c62030cb3b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Partners-with-Academic-Scientists-and-Biotechnology-Entrepreneurs-to-Create-the-California-Institute-for-Biomedical-Research-Ca-MRHBO.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742238\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742238"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}